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Background: Advances in genomics have led to calls for returning information about medically actionable
genes (MAGs) to patients, research subjects, biobank participants, and through screening programs, the general
adult population. Which MAGs are returned affects the harms and benefits of every genetic testing endeavor.
Despite published recommendations of selection criteria for MAGs to return, scant data exist regarding how
decision makers actually apply such criteria.
Methods: The process and criteria used by researchers when selecting MAGs for a preventive genomic sequencing
program targeting the general adult population were examined. The authors observed and audio-recorded the gene
selection meetings, and analyzed meeting transcripts, gene scoring sheets, and meeting handouts.
Results: To select MAGs, the committee imported, from a preexisting project, ‘‘a semiquantitative metric’’ that
scores genes on five criteria. Numerous subjective judgments and conceptual challenges in defining and ap-
plying the five criteria complicated the selection process. Criteria-related challenges also included the limited
evidence available about facts fundamental to the scoring decisions and the emergence and application of
criteria that were not part of the original metric.
Conclusions: When identifying MAGs appropriate for screening and return, decision makers must expect and
prepare to address such issues as the inevitability of subjective judgments, limited evidence about fundamental
decision-making elements, the conceptual complexity of defining criteria, and the emergence of unplanned
criteria during the gene selection process.
Keywords: medically actionable genes, genetic screening, return of individual results
Introduction
As genome-scale sequencing becomes cheaper andmore commonplace, and as more genomic information
is perceived to have medical utility, two related questions
regarding the return of genetic results become critical: which
genes should be analyzed for pathogenic variants, and how
should those genes be chosen? The answers are already rel-
evant in clinical practice and are gaining relevance in other
settings: in public health, if population-based preventive
genomic sequencing (PGS) becomes a reality, and in bio-
banking, as some biobanks return findings to their identified
participants (Henderson et al., 2013; Cadigan et al., this
volume). To inform emerging practice in these various set-
tings, this case study addresses these two important questions
in the context of PGS through examination of the gene se-
lection process in a novel ongoing study called GeneScreen,
which we describe in more detail below.
A key concept in answering these questions is medically
actionable genes (MAGs): those genes that may contain
pathogenic variants associated with a poor health outcome
that can be mitigated by an available intervention. Approxi-
mately 0.5–1% of people are estimated to carry deleterious
variants in MAGs (Evans et al., 2013). Despite this small
percentage, proponents of public health genomics argue that
if screening for MAGs occurred opportunistically (e.g.,
whenever whole genome or exome sequencing [WGS/WES]
is conducted for clinical or research purposes) or at the
population level through PGS programs, millions of people
who unknowingly carry medically actionable pathogenic
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variants could be identified (Evans et al., 2013; Green et al.,
2013; Berg et al., 2016).
However, genetic experts disagree about which genes
should be considered MAGs and returned to individual pa-
tients, research subjects, or biobank participants (Fullerton
et al., 2012; Berg et al., 2013; Goddard et al., 2013; McGuire
et al., 2013; PCSBI, 2013; van El et al., 2013; Wolf et al.,
2013; Jarvik et al., 2014; Klitzman et al., 2014). Due to un-
certainty in identifying pathogenic variants (Richards et al.,
2015; Van Driest et al., 2016) and limited data about their
penetrance in the general population (Green et al., 2013;
Prince et al., 2014; Adams et al., 2016), groups that return
findings from MAGs risk unnecessary medicalization, espe-
cially for people without symptoms or family histories of
genetic conditions, potentially leading to overtreatment, un-
warranted anxiety, and other harms (Burke et al., 2001, 2013;
Khoury et al., 2008; Klitzman et al., 2013; Prince et al., 2014;
La´zaro-Mun˜oz et al., 2015; Levine and Steinberg, 2015;
Adams et al., 2016). The prospect of harm makes it vitally
important to base the choice of which genetic results to return
on well-researched criteria and sound selection processes.
The first attempt to address which specific MAGs should
be returned at the policy level occurred in 2013, when the
American College of Medical Genetics and Genomics
(ACMG) published its recommendations regarding MAGs to
analyze and report to patients whenever WGS/WES is per-
formed for clinical purposes (Green et al., 2013). The rec-
ommendations came from an ACMG-appointed Working
Group that utilized a deliberative expert consensus process to
develop a list of 57 (later reduced to 56) genes that should be
analyzed for actionable pathogenic variants, and the results
returned. In November 2016, the list was increased to 59
genes (Kalia et al., 2016).
The 2013 ACMG recommendations generated significant
critiques (Burke et al., 2013). These included complaints that
the process for developing the guidelines was not sufficiently
‘‘deliberative and inclusive’’ (Ross et al., 2013:525) and that
‘‘[t]he broad criteria used [to select genes] would actually
justify a much longer list of genes’’ that can affect the rep-
licability of the selection process (Wolf et al., 2013:1050).
Citing the 2011 National Academy of Medicine’s (NAM)
recommendation of eight standards to use to develop clinical
practice guidelines (IOM, 2011), Ross et al. (2013) argued
that the ACMG Working Group failed to meet most of the
standards, including involving diverse stakeholders in deci-
sion making and eliminating bias due to conflicts of interest.
Despite such critiques, the ACMG recommendations are used
not only in clinical care but also in research settings. For
example, Geisinger Health System aims to recruit over
100,000 of its members to participate in the ‘‘MyCode
Community Health Initiative.’’ This precision medicine
project and biobank will return results for 76 MAGs (asso-
ciated with 27 health conditions), the bulk of which are the
ACMG 56 (Geisinger, 2016).
The Geisinger MyCode project is by no means the only
biobanking effort to return MAGs findings to individuals.
One large-scale example is the Precision Medicine Initiative,
which aspires to return individual and cohort-level results to
its million or more participants (Collins and Varmus, 2015).
Many scholars have written on the responsibilities of bio-
banks to return individual results to participants who indicate
they want them, and the criteria to assess which results should
be returned (e.g., Wolf et al., 2012; Holm et al., 2014). The
criteria almost always hinge on medical actionability.
As genomic research advances, the number of genetic
variants defined as medically actionable will increase. With
this in mind, Berg et al. (2016) developed a ‘‘semiquantita-
tive metric,’’ a scoring mechanism to use for assessing the
medical actionability of gene-disease pairs. The metric re-
sponds to some of the critiques of the ACMG process in an
effort to create a replicable tool that selection committees
could employ to examine actionability in different contexts.
The ‘‘semi’’ in Berg et al. (2016:472) semiquantitative metric
was intended to suggest the ‘‘nuances in application’’ of the
metric, specifically the ‘‘subjectivity inherent in scoring.’’
The metric was thus designed to promote rigor and trans-
parency in gene selection, while at the same time allowing for
some degree of flexibility in its application.
In this article, we critically examine a gene selection
process to better understand the subjectivity that Berg et al.
(2016) note. We perform this assessment through an ethno-
graphic study of the deliberations of a committee of re-
searchers (the Gene Selection Committee [GSC]) as they
used Berg et al. (2016) semiquantitative metric to facilitate
decision making in their analysis of candidate genes for a
research project called GeneScreen. With support from the
National Human Genome Research Institute of the National
Institutes of Health (NIH), GeneScreen is developing one of
the first PGS pilot programs targeting the general adult
population. It aims to screen 1000 adults, return results of
MAGs to participants, and analyze the ensuing harms and
benefits of screening (Prince et al., 2014; GeneScreen Pro-
ject, 2016). GeneScreen recruits individuals for screening
through two mechanisms: patients in general medicine clin-
ics in North Carolina, and participants in a Kaiser Permanente
biobank. GeneScreen researchers from the University of
North Carolina (UNC) and Kaiser Permanente hope to obtain
further funding to expand GeneScreen to include 20,000
additional Kaiser Permanente biobank participants.
Our real-time ethnographic study was designed into Gene-
Screen to enhance transparency and provide useful data to
inform future gene selection efforts. The ethnographic study
was intended to be inductive and open to issues as they
emerged. The management of the subjectivity that Berg et al.
(2016) foresaw—that is, the inevitably messy interaction
between quantification and human judgment—immediately
emerged as a critical issue, and it is the focus of this article.
To our knowledge, this is the first published report of an
observational study of an actual MAGs selection process.
Overview of GeneScreen’s gene selection process
GeneScreen’s GSC was composed of researchers whose
fields include medical genetics, genetic counseling, bioethics,
law, anthropology, philosophy, sociology, psychology, and
nursing. A medical geneticist chaired the committee. Berg
et al. (2016) originally developed the semiquantitative metric
for use in a separate study called NCGENES (North Carolina
Clinical Genomic Evaluation byNextGen Exome Sequencing)
(Berg et al., 2016 description of the metric reflects some slight
revisions from the version used by GeneScreen). Several GSC
members are also researchers in NCGENES.
NCGENES is part of the NIH-funded Clinical Sequencing
Exploratory Research consortium (CSER, 2016). It examines
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the utility of WES for identifying underlying genetic cau-
ses of undiagnosed conditions in several patient popula-
tions (e.g., cancer and cardiac diseases) (Foreman et al.,
2012; NCGENES, 2016). Using the metric, NCGENES
identified 168 MAGs to be opportunistically screened
as secondary targets and returned to patient-participants,
in addition to primary target genes associated with their
symptoms.
GeneScreen’s GSC evaluated candidate genes for genomic
screening in the general adult population. The GSC started
with the metric and scores developed in NCGENES. The
metric scores genes based on five criteria: (1) severity of
disease outcome, (2) likelihood of severe outcome, (3) ef-
fectiveness of intervention, (4) acceptability of the inter-
vention, and (5) knowledge base about the first four criteria
(Berg et al., 2016) (Table 1). Each criterion was scored from
0 to 3 (as wewill discuss, knowledge base was initially scored
from 0 to 2, but later changed) and scores were added to
obtain a total score, with each candidate gene having a
maximum possible score of 15. In theory, the higher the
gene’s total score the more suitable it would be for general
population screening and return. GeneScreen’s nine-member
community advisory board (CAB) was also consulted about
some GSC decisions.
Methods
This case study of GeneScreen’s GSC meetings took place
at UNC-Chapel Hill. UNC’s Institutional Review Board
evaluated the protocol and determined it to be exempt from
review. All authors are GeneScreen researchers and three
wereGSCmembers. At least one of the anthropologist authors
attended each of the seven 1-h long GSC meetings as a
participant-observer. The meetings were recorded and tran-
scribed. The results presented here are based on the authors’
analyses of the GSC meeting transcripts, gene scoring sheets
and other meeting handouts, and the authors’ notes of the
meetings. The authors reviewed the meeting transcripts and
other documents, discussed the structure and dynamics of the
decision-making process, identified emerging topics such as
occurrences of subjective judgments, developed a coding
scheme related to the criteria used to select genes for the
screening program, and coded the transcripts usingATLAS.ti.
The authors then reviewed the ATLAS.ti-generated transcript
excerpts. These excerpts were divided among the authors who
analyzed how the criteria were applied and drafted reports for
each code. The authors reached a consensus regarding each
code report, revised the drafts, and approved the final version
of each report.
Table 1. Semiquantitative Metric: Official Criteria
Criterion Guiding question Scores
Severity What is the nature
of the threat to
health for an
individual carrying
a deleterious allele
in this gene?
3 =Death with no chance to intervene
2 =Diagnosis with death as distinctly possible outcome
1 = Significant morbidity
0 =Modest or no morbidity
Likelihood What is the chance
that a serious
threat will materialize?
3 = >50%
2 = 25–49%
1 = 5–24%
0 = <5%
Effectiveness How effective
are interventions
for preventing the harm?
3 =Highly effective
2 =Modestly effective
1 =Minimally effective
0 =Not effective
Acceptability How acceptable
are the interventions
in terms of the burdens
or risks placed on the individual?
3 =Highly acceptable
2 =Modestly acceptable
1 =Minimally acceptable
0 =Not acceptable
Knowledge What kind of evidence
is available to score
severity, likelihood,
effectiveness, and acceptability?
At the beginning of the gene selection process:
2 =A great deal is known about the condition,
the gene and the above parameters
1 =Adequate body of knowledge exists to make
clinical decision and recommendations when necessary
0 = Insufficient knowledge of above parameters
to make decisions about intervention
During the gene selection process it was modified to:
3 = Substantial evidence
2 =Moderate evidence
1 =Minimal evidence
0 =Controversial or poor evidence
The information was obtained from one of the handouts provided to GSC members during GeneScreen’s gene selection process. Given
GeneScreen’s connection with NCGENES, that handout has some similarities to table 1 in Berg et al. (2016).
186 LA´ZARO-MUN˜OZ ET AL.
Results
Results below are divided into three sections. First, we de-
fine subjective judgments and illustrate how these judgments
affected important aspects of the gene selection process. Next,
we detail the complexity of applying each of the metric’s
‘‘official’’ criteria and some of the subjective judgments that
influenced gene scoring. Finally, we describe ‘‘unofficial’’
criteria that emerged during the selection process that proved
important in selecting genes to screen in this context.
Subjective judgments
Subjective judgments are determinations where reasonable
individuals could reach differing conclusions upon evalua-
tion of the available information, or ‘‘judgments that may be
contested’’ (Miller et al., 2014). The 2011 NAM report for
developing trustworthy clinical practice guidelines warns
that subjective judgments often pass unnoticed but ‘‘impor-
tantly influence conclusions’’ (IOM, 2011:122). As the cre-
ators of the metric have acknowledged (Berg et al., 2016), the
metric’s application to a specific context inevitably involves
subjective judgments that cannot be viewed as directly
compelled by evidence. Subjective judgments are more
common when there is a lack of evidence or conflicting ev-
idence on the issue in question (IOM, 2011). Given the lack
of research and evidence about many aspects of population-
based PGS programs and some other genomic testing en-
deavors (Prince et al., 2014; Manrai et al., 2016), it is not
surprising that subjective judgments were common during
the GSC gene selection process.
An illustration of the nature and importance of subjective
judgments was observed early in the GSC’s deliberations. It
involved the fact that GeneScreen would be inviting people
from the general population to be screened for genetic con-
ditions. Some GSC members made the judgment that such a
program should have stricter gene inclusion criteria than one
that opportunistically screens for variants in genes for which
the sequencing data have already been generated for research
or clinical purposes. As a GSC member commented:
In NCGENES we’re saying ‘‘We’ve done [WES] sequencing
anyway. We.got the results. Now what do we do with it?
And here are the ones we feel we should return.’’ Very dif-
ferent than [GeneScreen where we are] saying ‘‘We’re gonna
go out into the population, and we’re gonna look to see if you
have mutations in these genes.’’
The argument against this distinction is that—like indi-
viduals from the general population—those who are oppor-
tunistically screened for pathogenic variants in secondary
target MAGs generally lack symptoms or a family history of
the secondary conditions examined. It would thus be rea-
sonable to conclude that both groups are exposed to similar
harms and benefits related to unsuspected pathogenic variants
in MAGs, and the fact that raw sequencing data have been
generated in one context but not the other does not justify a
different threshold. Furthermore, there is no research avail-
able to suggest that the harms and benefits of screening for
unsuspected genetic conditions in these two groups differ in
meaningful ways. Therefore, the higher inclusion threshold
for general population screening was a subjective judgment
that had a significant impact on the number of genes that were
even considered for GeneScreen. GeneScreen only consid-
ered 41 of the 168 MAGs from NCGENES because the GSC
established a preset score threshold of ‡11.
Despite the semiquantitative metric’s apparent simplicity,
its application proved complex, and the complexities often
involved subjective judgments. Moreover, it also became
evident that subjective judgments related to factors outside the
metric criteria played a significant role in the decision-making
process (see Unofficial Criteria section). Recognizing this re-
ality, one member cautioned the GSC: ‘‘The metric isn’t ev-
erything. The metric guides us but is not definitive. We can’t
just blindly turn the crank and say we should screen for these.’’
Official criteria
In this section, we present data on how the metric’s five
‘‘official’’ criteria were applied, detailing the challenges that
emerged during the GSC’s deliberations and highlighting
some of the subjective judgments that played important roles
in shaping gene scoring and selection (Tables 1 and 2 for
GeneScreen’s final list of genes and their scores).
Severity. Severity was a critical criterion, and one
fraught with subjective judgments. The GSC decided that the
more severe the potential health outcome associated with a
gene, the greater the justification for inclusion. In fact, one
member suggested that any gene associated with conditions
that scored on the lower end (0 or 1) of the severity scale
should be automatically excluded.While no ‘‘auto-fails’’ were
integrated into the scoring system, none of the candidate genes
had a severity score of 0 and very few scored a 1. Death was
regarded as the worst possible outcome, but the only genes that
received the highest score of 3 were those associated with
conditions for which, as a GSCmember described, ‘‘you could
drop dead all of a sudden’’ (e.g., aortic dissection and cardiac
arrhythmia). Genes associated with conditions for which death
is a longer-term possibility (e.g., colorectal cancer and familial
hypercholesterolemia) received a 2.
Genes associated with multiple, distinct severe health
outcomes were particularly complicated to score for severity.
When examining these genes, the GSC considered three
alternatives: score (1) the most severe outcome, (2) the most
penetrant outcome, or (3) multiple outcomes. The usual
practice was to score ‘‘the worst’’ outcome, as a member
commented. For example, for FBN1—associated with Mar-
fan syndrome—aortic dissection was scored instead of any of
the ocular or skeletal phenotypes also associated with the
condition (Dietz, 2014). However, another member coun-
tered, ‘‘We’re not consistent.sometimes it’s the worst, and
sometimes it’s the more likely. Because for BRCA we did
breast cancer. I would argue ovarian cancer is worse.’’
Similarly, for Lynch syndrome-associated genes, colorectal
cancer—the most likely health outcome—was selected over
ovarian or gastric cancer (Kohlmann andGruber, 2014), which
some might argue are more severe and difficult to manage.
Choosing which outcome to score was a subjective judgment
with critical implications for the decision-making process
because it largely determined the scores for the other four
metric criteria. Furthermore, there was no clearly stated reason
as to why the GSC usually scored the most severe condition
associated with a gene but in some cases scored the most
penetrant, despite internal discussion of this discrepancy.
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Likelihood. The likelihood of developing a severe outcome
influenced the selection process, but did not generate as many
subjective judgments as the other metric criteria. This may
be due to the relative clarity of the definition—synonymous
with penetrance—and the fact that, unlike the other criteria,
likelihood is objectively quantifiable. As one member said,
‘‘penetrance.is what it is.’’ The GSC did acknowledge that
current calculations likely overestimate penetrance in the
general population, yet decided to use these estimates none-
theless. Referencing the penetrance of Romano-Ward Long
QT syndrome-associated variants, a member commented:
It’s probably not as high as we think because we’ve always
ascertained these people by looking at all the people who have
had lethal dysrhythmias. We haven’t been looking at the
people who have mutations who didn’t come to the doctor
cause they didn’t have lethal dysrhythmias.
Initially, the general consensus was that likelihood
‘‘should not loom super large’’ in the selection process.
However, later meetings highlighted concerns that it is im-
portant to consider penetrance to minimize the risk of over-
diagnosis and overtreatment in the general population.
Ultimately, the vast majority of genes selected were associ-
ated with highly penetrant conditions (scores of 2 or 3) and
only two of the genes selected, HFE and RYR1, scored a 1.
Effectiveness. Effectiveness of intervention was a com-
plex assessment in which subjective judgments—in the sense
of judgments that seemed to be based on personal preferences
that could be contested—were influential. On the one hand, a
gene that might score high in other categories could score
poorly in effectiveness and be disregarded. Amember warned:
I do notwant to go out looking for stuff in people. Say [to them],
‘‘You’ve got a disease that could be severe’’ and say, ‘‘By the
way, we really don’t have very good ways of dealing with it.’’
On the other hand, a gene that scored poorly in other ca-
tegories could still make the list if an effective and acceptable
intervention was available. This occurred in the case ofHFE,
a gene associated with hemochromatosis:
The penetrance isn’t high.. it should get dinged as it does on
our metric with that, but it is more than compensated for by the
fact that you’ve got this really acceptable, absolutely effective
intervention.. which is phlebotomy.
These examples suggest that—although the metric did not
differentially weight criteria—in practice, a criterion like
effectiveness, at times was given more weight by decision
makers than criteria such as severity and likelihood.
Scoring conditions with multiple possible effective in-
terventions was particularly difficult. Some GSC clinicians
argued for scoring the intervention they personally would
initially recommend, which often involved a subjective
judgment that balanced the effectiveness and burden of the
possible interventions. For example, double mastectomy
was the intervention scored for BRCA1/2 mutations instead
of increased surveillance, which the GSC considered less
burdensome. A clinician stated, ‘‘What I tell [patients] is,
‘if you choose surveillance, you’re doing nothing to pre-
vent. The only way to prevent breast cancer is bilateral
mastectomy.’’’
For other genes, a less effective but more acceptable in-
tervention was chosen. For example, when discussing inter-
ventions for Romano-Ward Long QT syndrome, a member
commented:
[Beta-blockers are] moderately effective.certainly not a
guaranteed success.. The ICD [implantable cardioverter
defibrillator] actually is highly effective.. If you score ICD,
you’d get a higher effectiveness but a lower acceptability.
Ultimately, the GSC scored electrocardiogram (EKG)
screening as the recommended intervention. Like beta-
blockers, EKG screening was considered moderately effec-
tive, but highly acceptable.
Some clinician members also expressed concern about the
efficacy of behavioral interventions. This revealed a bias
among clinicians toward endorsing genes associated with
conditions for which there are ‘‘medical’’ interventions, and
generated sharp disagreements along disciplinary lines. A
medical geneticist noted:
[B]ehavioral interventions.. They’re weak.. They’re hard
to implement. They nudge risk. Right. And I think that com-
bined with the weakness of most genetic predictors is what is
responsible for the failure of public health genomics so far.
A social psychologist countered that behavioral interven-
tions might only seem weak because their effectiveness is
often assessed before their impact can be measured. This
dispute was particularly sharp in the case of SERPINA1,
whose related condition (alpha-1 antitrypsin deficiency) is
managed primarily by smoking avoidance; the gene was ul-
timately included.
Acceptability. Acceptability of the recommended inter-
vention was an important but challenging consideration. A
GSC member commented:
We could go searching for CDH1 mutations that cause a high
risk of gastric cancer.. We have [a] very good interven-
tion.Here’s the problem.the only intervention is removing
your stomach which is not only a big surgery,.it’s a tough
way to live. To ignore acceptability would mean that it
would score very highly, and I actually would feel real trou-
bled by us going out into the general population and screening
for something where the only intervention is that.
Acceptability was acknowledged by the GSC to be ‘‘the
most subjective’’ of all criteria, and its scoring was described
as ‘‘squishy.’’ This was in part due to the difficulty of defining
acceptability and the lack of relevant research in the context
of population-based genomic screening. Scoring acceptabil-
ity involved numerous subjective judgments. For example, to
facilitate decision making, acceptability was determined by
comparing interventions associated with different genetic
conditions under consideration. As a GSC member com-
mented, ‘‘It’s not just ‘Where would you put colonoscopy?’
it’s ‘How does colonoscopy rate relative to having your
stomach out relative to an annual blood test?’’’
Furthermore, when evaluating the acceptability of an in-
tervention, the GSC decided to downplay the impact of
contextual features such as participant characteristics, cost of
interventions, severity, and likelihood of a severe outcome.
Some GSC members questioned this decision, and suggested
that a burdensome intervention may become more acceptable
if the likelihood of developing a severe outcome is high.
However, the approach followed by the GSC was typified by
this comment:
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The slippery slope is [that] if it means I’m gonna die, every-
thing’s acceptable.. To me the way to look at acceptability is
you pluck somebody out of the population, you don’t tell them
the context, and.you do a colonoscopy.. How burdensome
is that versus.you draw their blood?’’
Some GSC members were concerned about whose per-
spective should be used to score acceptability: that of clini-
cians, researchers and academics, or the general public? A
clinician member suggested that the CAB could help score
acceptability because ‘‘[W]e have tried very hard to ignore
the fact that we’re clinicians when we come up with the
acceptability scores.. [But] we have no idea if we’re right
compared to the lay person.’’ As it turned out, at a subsequent
CAB meeting, CAB members had little consensus regarding
acceptability scoring. Unlike the approach ultimately fol-
lowed by the researchers, CAB members were reluctant to
score acceptability without considering multiple contextual
features such as those mentioned above. The CAB’s nuanced
view of acceptability resisted the orderly metric scoring and
further highlights the subjective nature of this criterion.
Knowledge base. The metric’s knowledge criterion is
intended to ensure that claims about the other criteria are sci-
entifically well-founded. However, knowledge base proved
to be a moving target. Early in GeneScreen’s selection pro-
cess the GSC interrogated the knowledge criterion imported
from NCGENES. An initial problem was that NCGENES
scored knowledge on a three-point scale (0, 1, 2) that some
GSC members believed did not provide sufficient gradation
or guidance (Table 1). One GSC member characterized it as
‘‘knowledge good or knowledge bad.’’ The same member
highlighted a key underlying problemwith defining knowledge
base:
[T]here is a difference between relying on what people in my
field say and my clinical experience. ‘‘This is how confident I
am at doing this.’’.Which is how some people define
knowledge base. And other people define it as, ‘‘Can I find a
journal article in a peer reviewed journal that looked at people
who did different things and got different outcomes?’’
GSC members believed it was particularly important to be
rigorous when assessing knowledge base in the context of gen-
eral population screening. As one member advised, ‘‘The last
thing.we should do is be running out and looking for prob-
lems in people when we really don’t even understand the dis-
ease, the interventions, the process.’’ Anothermember proposed:
I’m thinking of a three-point [in fact, four-point—0, 1, 2, 3]
knowledge base scale. [T]hree would be things that have
primary literature about the condition itself. Two would be
things where there’s a biological similarity to a different
disease that has good literature.like PTEN and breast cancer.
[O]ne is.where we’re really hand waving and saying ‘Well,
expert opinion says, but nobody has studied.’ Then zero is
[where there is controversial or poor evidence].
The GSC agreed to revise the criterion as suggested,
adopting an expanded scale with each score defined more
rigorously. This likely helped minimize subjectivity, but at
some points clinician members used their own clinical ex-
perience to resolve ambiguities in applying the revised scale.
Unofficial criteria
Other decision-making elements beyond the official metric
criteria influenced the gene selection process. We labeled
these informal but powerful factors the ‘‘unofficial criteria’’
(Table 3). These unofficial criteria—population prevalence,
cost of sequencing the gene, and age of onset of the associated
Table 3. Unofficial Criteria That Influenced Gene Selection
Criterion Rationale Illustrative quotes
Population prevalence
of pathogenic
variants in the gene
Because GeneScreen will only enroll
1000 participants, screening genes
with low prevalence of pathogenic
variants will not advance the research
aim of understanding the implications
of returning a positive result.
‘‘Something that has a mutation prevalence of one
in a million there’s not much point in looking
for it in our sample of a thousand people.’’
‘‘There are two syndromes on this list that have
a high enough population prevalence where
we’re going to find them: Lynch Syndrome and
BRCA1/2. Cumulatively they have about a one
in two hundred population prevalence.. That’s
where the money is for us.’’
Cost of sequencing
the gene
GeneScreen has a set budget and sequencing
large genes increases costs. Also, the
prevalence of pathogenic variants in some
genes is low enough that they would
increase costs, but are not likely to yield
positive results in the study’s sample.
‘‘We are constrained by costs.. we will probably
have to factor in how big is the gene.’’
‘‘[APC is] a big gene, and it’s going to cost a
lot of money [to sequence].’’
Age of onset GeneScreen targets the general adult
population. For conditions that express
before adulthood, participants would
likely already be impacted by the
condition, which reduces the utility
of genomic screening for that
condition in adults.
‘‘The idea of doing little kids and looking at their
APC gene that causes familial polyposis coli
with essentially a 100% cancer rate [and is]
highly intervenable.that would make a lot
of sense to me. But we’re doing adults, and if
the average age of our participants if forty, the
chance that they’re going to have a previously
undetected APC mutation is really low.’’
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condition—were largely motivated by GeneScreen’s specific
context, research questions, and budgetary limits, but their
emergence also highlighted the pervasive influence of sub-
jective judgments in the gene selection process.
Population prevalence. The prevalence of pathogenic
variants in MAGs was an influential consideration. Pre-
valence of pathogenic variants is, of course, quantifiable, and
is thus objective in one sense. But the decision to consider
prevalence even though it was not part of the official criteria
and, ultimately, to give it great weight were subjective
judgments. A GSC member argued, ‘‘Something that has a
mutation prevalence of one in a million there’s not much
point in looking for it in our sample of a thousand people,’’
and later added, ‘‘we should have a tight, high-yield list.’’
The same member also commented: ‘‘There are two syn-
dromes on this list that have a high enough population
prevalence where we’re gonna find them. It’s Lynch Syn-
drome and BRCA1/2. Cumulatively they have about a one in
two hundred population prevalence.. That’s where the
money is for us.’’
Prevalence became such a central consideration that it was
added to the scoring sheet alongside the official criteria
scores, a status not accorded the other unofficial criteria.
Discussions about prevalence prompted one member to ask,
‘‘So is frequency a new category?’’ Another replied, ‘‘No,
but it’s a consideration.’’ Concerns about low prevalence
were key for the exclusion of some genes that scored high on
the metric (i.e., ‡11), including VHL, PTEN, TGFBR 1, and
TGFBR 2. In contrast, high prevalence favored inclusion of
genes ‘‘dinged’’ on other grounds, such as SERPINA1with its
‘‘weak’’ behavioral intervention and HFE with its low pen-
etrance. Prevalence thus led the GSC to reject some higher
scoring genes from the final list and to include some with low
scores on certain criteria.
Cost of sequencing the gene. Early in the selection
process a GSC member argued that the list should be short
because ‘‘something meeting our rigorous criteria will be
somewhat unusual, and secondly we are constrained by
costs.. we will probably have to factor in how big is the
gene.’’ When discussing the possible inclusion of APC, the
same member commented, ‘‘It’s a big gene, and it’s gonna
cost a lot of money [to sequence].’’ APC was eventually kept
on the list, but other genes such as TTN were excluded be-
cause of their size. A member commented, ‘‘Well, why not
screen for TTN.? Well, it’s gigantic,’’ later adding, ‘‘it’s
cost.’’
The cost of sequencing was also often cited as a reason for
excluding high-scoring genes with low prevalence of path-
ogenic variants. A member argued that genes associated with
pathogenic variants that occur in one in a million individuals
should not be included ‘‘even if [they] meet our other criteria,
[because] it costs money to do this.’’ Including these genes
would increase costs but would not advance GeneScreen’s
research goal of studying the impact of disclosing positive
findings to participants from the general population. Cost
thus exerted influence but specific costs were never estimated
or discussed in relation to the budget.
Age of onset. GeneScreen was designed to target the
general adult population. Therefore, some GSC members
were concerned that including genes associated with condi-
tions that present before adulthood would undermine the
utility of the screening. One member argued, ‘‘The whole
point of screening is to find something early so you can
prevent a problem. If people are gonna have the problems [by
the time they participate in the program], then why would you
waste time screening?’’ One member argued against con-
sidering age-based risk because of concerns about the lack of
data on age of onset for many genetic conditions. Others felt
uncomfortable about excluding conditions that generally
have an early age of onset because some individuals could
nonetheless begin experiencing symptoms later in life. Age
of onset issues were considered when evaluating the utility of
screening for pathogenic variants in genes such as APC, RET,
FBN1, BRCA 1, and BRCA 2. For example, when evaluating
APC a clinician commented, ‘‘we’re [screening] adults.if
the average age of our participants is forty, the chance that
they’re gonna have a previously undetected APC mutation is
really low.’’ The discussion of this factor was episodic and
the GSC set no general standards.
Discussion
In this study of one of the first attempts at selecting
genes for an adult PGS program (a program that recruits
participants through clinic populations and through a
healthcare organization’s biobank), we have focused on the
subjective judgments that arise when a group attempts to
select MAGs to examine and results to return. This analysis
is useful not only for those interested in implementing PGS
programs, but also for biobankers and other researchers
who are under increasing pressure to return medically ac-
tionable individual results to participants (Wolf et al.,
2012; Jarvik et al., 2014). Even for biobankers and re-
searchers focused on populations with specific diseases,
this analysis of scores relevant to screening asymptomatic
adults remains relevant given that any secondary findings
that are returned may be unrelated to the disease and not
indicated by any symptoms or family history. Berg et al.
(2016:473) acknowledge ‘‘the necessarily subjective nature
of any assessment of actionability,’’ and recommend that
‘‘the scores and evidence base generated by the application
of the semiquantitative metric are best considered an initial
starting point for more nuanced discussions about indi-
vidual conditions or particular clinical applications.’’ In
this article, we explored the subjectivity in the application
process and the discussions and decision making that oc-
curred when the metric was used to select genes that would
be examined and returned in a genomic testing program.
Subjective judgments in the application of the metric are
problematic because they add arbitrariness to the pro-
cess and threaten its reproducibility. A rigorous and well-
informed gene selection process is an essential first step for
any genomic testing endeavor because it can help properly
manage subjective judgments, and maximize the benefits
and minimize harms of testing.
In future gene selection processes, some of the specific
challenges that introduced subjectivity into the GSC process
could be more effectively managed through advance plan-
ning. Below we discuss some key lessons revealed by our
analysis that may be particularly helpful when using a metric
to identify MAGs to return to individuals.
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Managing subjectivity with diverse stakeholders. The
2011 NAM report recommends that groups consist of indi-
viduals from clinical and nonclinical disciplines with repre-
sentation from more than one clinical specialty and from the
general public, including patients and caregivers (IOM,
2011:83–86). NAM bolsters its recommendation for clinician
diversity by citing studies showing that clinicians have a
‘‘lower threshold’’ for recommending procedures performed
within their own specialty (IOM, 2011:85).
The GSC did seek the views of the general public by asking
the CAB for assistance with scoring the acceptability of the
interventions, and the CAB’s response illustrated the poten-
tial for varying perspectives about how to evaluate this cri-
terion. CAB members felt they could not score acceptability
without considering contextual features, an idea that the GSC
had already rejected. Ultimately, it was not clear how, if at
all, the CAB’s perspectives were integrated into the GSC’s
decision-making process. One particular problem was that
CAB members were not invited to participate in the GSC’s
deliberative meetings; instead, the CAB met on its own, with
some GSC members observing and reporting the CAB’s
views back to the full GSC.
Furthermore, although a wide variety of nonclinical fields
were represented in the GSC, an analysis of speaking turns
showed that nonclinician members of the GSCwere much less
likely to speak during the GSC meetings compared to clini-
cians. Most nonclinicians seemed to lack sufficient knowledge
about the specific genes to contribute substantially—or even to
attempt to contribute—to conversations about most of the
criteria on the metric. In addition, as stated above, there were
no CAB members in the gene selection deliberative meetings.
Together, this meant that genetic clinicians had a dispropor-
tionate influence on the MAG selection process.
The inability to incorporate the CAB’s views and the
disproportionate influence of clinicians raises an important
general question: what role should nonclinicians play in the
selection process? The category of nonclinicians can include
community members, academics, policy makers, and others.
The participation of diverse stakeholders in the selection
process can promote a balanced representation of interests
affected by genomic testing programs and encourage ques-
tioning from different perspectives, which can help identify
and address subjective judgments and shared assumptions.
Although the GSC membership was highly interdisci-
plinary, it lacked clinical diversity (all of the GSC clinicians
specialized in genetics), excluded community members from
deliberative meetings, and nonclinician academics were
much less likely to speak than clinicians. Furthermore, sim-
ply adding input from diverse stakeholders into a gene se-
lection process does not mean their perspectives will be
effectively integrated. Stakeholders have different perspec-
tives and levels of understanding about genomics, medical
care, and the ethical, legal, and social implications of geno-
mic testing programs, which can complicate communication
and make it difficult to integrate diverse perspectives. Future
initiatives should not only add diverse stakeholders, but
carefully consider how they can contribute to decisionmaking,
and what training may be necessary to help all stakeholders
contribute effectively.
Evaluating genes associated with multiple health out-
comes. Candidate genes are often associated with more than
one severe health outcome. While individuals identified with a
pathogenic variant in these genes will likely be informed that
they are at an increased risk of developing all of these outcomes
(Kocarnik and Fullerton, 2014), the variant will have different
penetrance levels for each potential health outcome and some
of these outcomes will not be medically actionable. Therefore,
a gene may meet metric criteria based on its association with
one medically actionable outcome, but it may not meet the
criteria for inclusion if other outcomes are considered.
Although some GSC members argued for scoring multiple
outcomes, GeneScreen’s GSC ultimately decided to score
just one outcome per gene regardless of pleiotropy (e.g.,
BRCA 1, BRCA 2; Table 2). This subjective judgment likely
was influenced by an interest in maintaining a user-friendly
metric and the constraints of time, given the need to move the
larger research project forward. However, in-depth exami-
nation of how to manage MAGs associated with multiple
health outcomes, and the possibility of integrating multiple
outcomes into calculations, should be considered by future
initiatives to more accurately assess the risks and benefits of
analyzing and reporting this type of MAGs. Furthermore,
while the GSC generally scored the most severe condition or
outcome, in some cases it scored the most penetrant, and
never developed an explicit policy about which of these to
score. Nor was it clear what drove this choice in individual
cases. Sometimes it seemed to be an ethical judgment based
on a hypothetical participant’s best interest, whereas in other
instances the choice seemed to reflect an unstated clinical
preference. This type of inconsistency should be acknowl-
edged and addressed to minimize arbitrariness. Future ini-
tiatives should carefully consider how they will manage such
decisions before they begin their gene selection process be-
cause of the potential impact on the ultimate list of genes and
the ensuing harms and benefits to those screened.
Availability of multiple interventions. A similar problem
was revealed when the GSC evaluated genes associated with
genetic conditions that have multiple possible interventions.
For outcomes that are medically actionable, interventions may
have different levels of effectiveness and burden. GSC mem-
bers made a subjective judgment when they decided that for
gene selection purposes they would score the intervention that
clinician members believed struck the best balance between
effectiveness and burden. However, others could decide to
score the intervention that patients most commonly select, the
most effective one, the one generally recommended by pro-
fessional organizations, or even multiple interventions. Dif-
ferent choices could lead to different assessments about the
medical actionability of a genetic condition, so future groups
need to carefully examine the respective harms and benefits of
each option.
Considering acceptability as a criterion. Some of the
dilemmas discussed in the preceding sections involve eval-
uation of the acceptability of an intervention, which under-
scores the problematic nature of defining and applying an
acceptability criterion. Furthermore, acceptability rests on a
subjective judgment motivated by the medical ethics princi-
ple of nonmaleficence. That is, the goal is to avoid harm by
not screening for and returning genomic health risks for
which the only available intervention would be viewed, at
least by some, as too onerous. However, one could argue that
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this is an unduly paternalistic approach and that individuals
carrying actionable genomic risks should have the opportu-
nity to decide for themselves whether the intervention is too
onerous. If future initiatives still decide to use acceptability
as a criterion, it will be important to acknowledge its inherent
subjective nature and manage it by carefully defining what is
acceptable and why, and whose perspectives should count in
scoring it. In addition, future initiatives could also try to
manage the subjective nature of criteria such as acceptability
and severity by examining the perspective of members of the
general population and professional clinical organizations
about the interventions and conditions under consideration.
Managing unofficial criteria. In addition to the official
criteria, the population prevalence of pathogenic variants in
each MAG, the cost of sequencing specific MAGs, and the
age of onset of symptoms of associated genetic conditions
also influenced the GSC’s decisions. Consideration of these
unofficial criteria does not necessarily suggest that the formal
gene selection process was flawed. Unofficial criteria pro-
vided a way to address important concerns specific to the
context of GeneScreen that were voiced only after the process
was underway. However, to minimize the impact of subjec-
tive judgments, such as the arbitrary use of decisional ele-
ments outside the official metric criteria, future selection
processes should consider at the outset whether the specified
decision-making tools contain all of the criteria that are likely
to be relevant for their context. If unofficial criteria emerge
during the process and are not promptly identified and in-
terrogated by decision makers, the process may be at risk of
arbitrariness. Decision makers must be poised to identify
such criteria, determine their utility, and then define and
transparently implement them as appropriate.
Limitations
Given the nature of a case study, our analysis is based on
the process and criteria employed by a single center. Fur-
thermore, the analysis is based on GeneScreen’s GSC
meetings and does not include discussions that may have
occurred outside of these meetings, nor deliberations about
the metric that occurred in the predecessor NCGENES pro-
ject. Many of GeneScreen’s investigators were also part of
the NCGENES process, and they may have brought to the
GeneScreen selection process shared assumptions or impor-
tant conclusions that are not captured in the data we con-
sidered. Thus, GeneScreen’s GSC meetings and the related
data provided a revealing but inevitably incomplete look into
several of the complicated issues that arise in selecting
MAGs for examination and return.
Conclusions
Our findings suggest that MAGs selection criteria such as
those utilized by GeneScreen are important guides in the
process, but those who use them ‘‘can’t just blindly turn the
crank.’’ Instead, decision makers should be reflective in de-
veloping and applying selection criteria, to ensure that those
criteria address all the relevant aspects of informed decision
making in the context at hand. At the same time, they should
strive to make sure that inevitable subjective judgments
and unplanned but influential criteria are acknowledged
transparently and assessed and managed with reference to
available evidence. Advances in genomic sequencing will
increase calls for both preventive genomic screening pro-
grams for the general population, and the development of
return of results policies for biobankers and other researchers.
The selection of genes to examine and return as a part of such
programs and policies requires close scrutiny to ensure that
these are advisable in the first place and that, if implemented,
they maximize their social and medical utility.
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